Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Lonca-T had 48% ORR (24% CR) in relapsed refractory LBCL. 32% of patients had >3 lines prior therapy, 58% refractory to last line of therapy. 10% of patients went on to CAR-T with 47% response rate.

Read the full article here

Related Articles